Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
The latest announcement is out from Evaxion Biotech ( (EVAX) ).
Evaxion Biotech is in advanced discussions with the European Investment Bank (EIB) to convert €3.5 million of its €7 million loan into equity, enhancing its capital structure by $3.7 million. This strategic move is designed to ensure compliance with Nasdaq listing requirements, improve financial flexibility, and reduce liabilities, thereby strengthening Evaxion’s position in the financial community.
More about Evaxion Biotech
Evaxion Biotech A/S is a clinical-stage TechBio company that leverages its AI platform, AI-Immunology, to develop immunotherapies for cancer, bacterial diseases, and viral infections. With a focus on personalized vaccines, Evaxion aims to transform patient care by providing innovative treatment options for diseases with significant unmet needs.
YTD Price Performance: -84.69%
Average Trading Volume: 57,724
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $5.68M
See more data about EVAX stock on TipRanks’ Stock Analysis page.